Practice Management of Crohn's Disease in 2015
Gastroenterology
Curriculum:
Practice Management of IBD
Practice Management of IBD
Credits:
1 ACPE 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
1 ACPE 1 ANCC Contact Hours 1 AMA PRA Category 1 Credit(s) ™
Launch Date:
August 25, 2015
August 25, 2015
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Gastroenterologists; Nurse Practitioners; Nurses and Physician assistants who work with gastroenterology practices and/or treat patients with IBD; Pharmacists
Relevant Terms:
Gastroenterology; inflammatory bowel disease; Crohn's disease
Gary R. Lichtenstein, MD
Gary R. Lichtenstein, MD Professor of Medicine Raymond and Ruth Perelman School of Medicine of the Univeristy of Pennsylvania Director, Center for Inflammatory Bowel Disease Department of Medicine Division of Gastroenterology Philadelphia, PA
Bio
Gary R. Lichtenstein, MD, FACP, FACG, AGAF is the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania.Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center, in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School Of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/ international principal investigator evaluating novel agents for therapeutic trials in the treatment of Ulcerative Colitis and Crohn’s disease.
A Fellow of the American Gastroenterological Association, the American College of Physicians and the American College of Gastroenterology, Dr. Lichtenstein has been listed in “Best Doctors in America” (inflammatory bowel disease), and has served as Medical Secretary for the American Board of Internal Medicine, Gastroenterology Section. He holds membership and committee positions in many professional societies at a national level, including the American Gastroenterological Association where he has served as the vice-chair of the clinical practice committee and practice economics committee and where he has served as chair of the clinical practice committee, the American Society for Gastrointestinal Endoscopy where he has served on the committee on training, the American College of Gastroenterology where he has served on the Education Committee, Programs Committee and the Nominations Committee. He recently served as a member of the research committee. He has been the chair of the abstract review committee for Inflammatory Bowel Disease for the American College of Gastroenterology. He is also a member of the Crohn’s and Colitis Foundation of America where he served at the national level as the chair of the membership committee of the Clinical Research Alliance, he has served on the national grants review committee and the national physician education committee. He additionally is a longstanding member of the American College of Physicians and the American Medical Association.
Dr. Lichtenstein has received numerous awards including the award for the top specialist in the University of Pennsylvania Health system- the Louis A. Duhring Award. He is the recipient of the Christina and Marie Lindback award- the top teaching award in the entire University of Pennsylvania. He has received the medical school teaching award the "Penn Pearls Award". He has received the Department of Medicine Housestaff teaching award - the "Donald B. Martin Teaching Award". He has received the Gastroenterology Division teaching award - the Sidney Cohen Teaching Award. He is listed in “The Best Doctors in America” - Inflammatory Bowel Disease and in Philadelphia Magazine-Listed among top Gastroenterologists for elderly in Philadelphia and Listed among top Gastroenterologists in Philadelphia (Special Focus: Inflammatory Bowel Disease). He is the recipient of the CCFA- Physician of the Year Award: Philadelphia and Delaware Valley Chapters.
In addition to having served on the Editorial Board of the journals Gastroenterology, American Journal of Gastroenterology, Inflammatory Bowel Diseases, World Journal of Gastroenterology, and Digestive Diseases and Sciences Dr. Lichtenstein serves as a former writer of Selected Summaries in the journal Gastroenterology and served as the section editor of Selected Summaries and the section editor of Print and Media Review in Gastroenterology for a 5 year term. He also has and currently serves as a reviewer for such journals as The New England Journal of Medicine, Gastroenterology, The Lancet, the Annals of Internal Medicine, Gut, Journal of Parenteral and Enteral Nutrition, the American Journal of Gastroenterology, the World Journal of Gastroenterology and the Journal of Clinical Gastroenterology. He is the executive editor of a newly PubMed indexed journal Gastroenterology and Hepatology and serves as Associate editor of Therapeutic Advances in Gastroenterology, The Physician and Sportsmedicine, Clinical Investigation, and is currently Assistant Editor-in-Chief of the World Journal of Gastroenterology. An invited lecturer at the local, national, and international levels, Dr. Lichtenstein is the author or coauthor of more than 250 peer-reviewed primary articles, chapters letters and editorials, and he has presented over 250 abstracts and edited 18 books. He has lectured at a national and an international level at over 300 invited conferences, symposiums and institutional grand rounds.
| 1. | Articulate increased confidence in the identification of CD and UC disease and recognize which patients will or will not likely benefit from use of biological therapies | 2. | Decide when patients will likely benefit from the use of biological therapies |
| 3. | List both the benefits and the risks of biological therapies | 4. | Describe increased competence in their ability to monitor patients with IBD who are on biologic therapies |
| 1. | Articulate increased confidence in the identification of CD and UC disease and recognize which patients will or will not likely benefit from use of biological therapies |
| 2. | Decide when patients will likely benefit from the use of biological therapies |
| 3. | List both the benefits and the risks of biological therapies |
| 4. | Describe increased competence in their ability to monitor patients with IBD who are on biologic therapies |
Course Director
Francis A. Farraye, MD, MSc
Course Director
Professor of Medicine, Boston University School of Medicine
Clinical Director, Section of Gastroenterology, Boston Medical Center (Boston, MA)
Professor of Medicine, Boston University School of Medicine
Clinical Director, Section of Gastroenterology, Boston Medical Center (Boston, MA)
DISCLOSURE POLICY STATEMENT
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
Faculty Disclosures
Gary Lichtenstein, MD is a consultant for the Abbott Corporation, Abbvie, Actavis, Alaven, Ferring, Hospira, Janssen Orthobiotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, Takeda UCB and Warner Chilcotte. He also receives research or grant funding from Ferring, Janssen Orthobiotech,Prometheus Laboratories, Salix Pharmaceuticals, Santarus, Shire Pharmaceuticals, UCB and Warner Chilcotte. Dr. Lichtenstein also receives honorarium as an editor for Clinical Advances in Gastroenterology, Gastroenterology and Hepatology(Gastro-Hep Communications), Springer Science and Business Media, as an author for McMahon Publishing and Up-To-Date and additionnally receives book royalties from Slack, Inc.
Off-Label Discussions
The faculty does plan on discussing unlabeled/investigational uses of a commercial product. The faculty will discuss the off-label use of azathioprines, 6-MP and methotrexate for treating Crohn’s Disease.
Planning Committee Disclosures
Michael Burk, Senior Program Manager, Boston University School of Medicine’s Continuing Medical Education Department, has nothing to disclose in regards to commercial support.
Ms. Patti-Ann Collins, Boston University’s Continuing Medical Education department’s Lead Nurse Planner, has nothing to disclose with regards to commercial support.
Frank Farraye, MD, our program course director, is a consultant for Abbvie, Braintree, Extract, Janseen, Pfizer and Takeda. He also receives grant/research support from Cubist, Exact and Prometheus.
Hannah Miller, MD Boston University’s Continuing Medical Education department’s independent CME content reviewer, has nothing to disclose with regards to commercial support.
Beth-Ann Norton, MS, RN, ANP-BC, Nursing Program Director for the Crohn's and Colitis Center Adult Nurse Practitioner Brigham & Women's Hospital, and BUSM’s nursing advisor for this activity, is a consultant for Abbvie and NPS/Shire.
DISCLOSURE ATTESTATION
Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any discussion of unapproved use of pharmaceuticals and devices occurs
DISCLAIMER
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
Non-Endorsement of Products
Continuing Nursing Education Provider Unit, Boston University School of Medicine’s provider status refers only to continuing nursing education activities and does not imply that there is real or implied endorsement by Continuing Nursing Education Provider Unit, Boston University School of Medicine or ANCC of any product, service, or company referred to in this activity nor of any company subsidizing costs related to the activity.
CREDIT DESIGNATION
Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACCREDITATION STATEMENT
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CNE Contact Hours: 1.0 all of which are eligible for pharmacology credit.
Boston University School of Medicine designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CNE Contact Hours: 1.0 all of which are eligible for pharmacology credit.
Nurses will receive contact hours after completion of an evaluation and claim for credit form.
Continuing Pharmacy Education CreditsThe University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Participation and completion of program evaluations at the conclusion of the program are required for a statement of credit. This knowledge-based activity is approved for 1.0 Contact Hours (0.1 CEUs). UAN: 0060-9999-15-027-H01-P. Expiration date: August 25, 2016.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™, nurses are entitled to receive 1.00 CNE contact hours, all of which is pharmacology credit worthy, and pharmacists will receive 1.0 Contact Hours(0.1 CEUs). Statement of credit will be available for physicians and nurses to print from the user history page. Pharmacists can print a statement of participation; CE statements are available from the CPE Monitor.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians, nurses and pharmacists who successfully complete the post-test and evaluation will resepectively receive CME, CNE or ACPE credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
*Note to Pharmacists: to receive CE credits you must submit your NABP ID number and birthdate. You will be prompted to submit this information at the end of the activity, after completing the posttest, when claiming your credits. This is mandatory and the CE credits are not valid unless an NABP ID and birthdate is submitted.
If you do not have an ID number you can obtain one at the following link:
Release Date: August 25, 2015
Expiration Date: August 25, 2016
Date of Most Recent Review: August 13, 2015
Program Code: E.IBD15UC
For questions about CME, please contact cme@bu.edu or www.bu.edu/cme.
To view Boston University’s Privacy Policy, please see http://www.bumc.bu.edu/cme/policies/.
COMMERCIAL SUPPORT
This continuing medical education activity is supprted by independent educational grants from Abbvie Inc., Takeda Pharmaceuticals International Inc. and from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
